Top 10 Gene & Cell Therapy Companies

Kite Pharma, a wholly owned subsidiary of Gilead Sciences, is the undisputed global leader in CAR-T cell therapy commercialization. Its flagship product Yescarta generated $1.5 billion in 2025 revenue, while Tecartus contributed $344 million. Kite operates four wholly-owned GMP-certified cell therapy manufacturing facilities across the United States and Europe, achieving a remarkable 14-day vein-to-vein turnaround time.

Strengths: Largest dedicated CAR-T manufacturing infrastructure worldwide; FDA removal of REMS requirements expanding community hospital access; strategic partnership with Cytiva for Sefia automated production platform; proven commercial execution with blockbuster Yescarta franchise; deep clinical expertise across multiple lymphoma indications.

Weaknesses: Significant Q4 2025 sales decline of 6% due to intensified competition from BMS Breyanzi; over-reliance on CD19-targeted CAR-T with limited pipeline diversification into other targets or indications; high operational costs from maintaining multiple large-scale manufacturing facilities.

Novartis has executed the pharmaceutical industry's most distinctive manufacturing transformation—shedding the high-volume, low-complexity generics production of Sandoz to concentrate its 33 global manufacturing sites entirely on advanced therapeutic platforms where production complexity creates durable competitive moats. The company's FY2025 net sales reached $54.5 billion, driven by core innovative medicines including Cosentyx ($4.5 billion in immunology), Entresto ($3.5 billion in cardiovascular), and a rapidly growing radiopharmaceutical franchise. Novartis's strategic manufacturing differentiation lies in its leadership across three manufacturing paradigms that generic CDMOs cannot economically replicate: radioligand therapy (RLT) production—operating a network of regional manufacturing facilities (in California, Indiana, New Jersey, and Italy) that synthesize, conjugate, and distribute lutetium-177 and actinium-225-based therapies within the hours-long window dictated by isotope half-lives; CAR-T cell therapy manufacturing—producing Kymriah through patient-specific autologous cell processing at centralized facilities requiring parallel supply chains for viral vectors, cell processing, cryopreservation, and patient-specific logistics; and traditional large-molecule biologics—maintaining significant monoclonal antibody and therapeutic protein capacity. The company invests over $10.5 billion annually in R&D (19.4% of revenue), maintaining one of the industry's deepest pipelines with over 200 active development projects.

Strengths: RLT manufacturing monopoly characteristics: Novartis's regional radiopharmaceutical production network—requiring proximity to both isotope production (nuclear reactors/cyclotrons) and treatment centers, specialized radiation safety infrastructure, and just-in-time logistics—creates barriers to entry that will limit competition for years. CAR-T manufacturing experience curve: Having manufactured thousands of patient-specific Kymriah doses since the first CAR-T approval, Novartis has accumulated process knowledge, supply chain refinements, and regulatory relationships that late entrants cannot easily replicate. Portfolio balance: The combination of traditional biologics manufacturing (providing stable revenue and capacity utilization) with advanced therapy platforms (providing growth and differentiation) creates a manufacturing portfolio that is both commercially resilient and strategically forward-positioned.

Weaknesses: Manufacturing transition execution risk: The Sandoz spin-off required separating intertwined manufacturing operations, quality systems, and supply chains—a multi-year process with ongoing residual complexity. RLT capacity constraints: Isotope supply (particularly actinium-225) is inherently limited by nuclear reactor and cyclotron availability, creating a hard ceiling on RLT manufacturing growth that is outside Novartis's direct control. CAR-T manufacturing cost structure: Autologous cell therapy manufacturing—with per-patient production costs of $50,000-$100,000 before any margin—faces long-term pressure from allogeneic (off-the-shelf) approaches that promise dramatically lower manufacturing costs if technical barriers are solved.

Bristol-Myers Squibb has built a focused, high-value biopharmaceutical manufacturing network centered on immuno-oncology, hematology, and cardiovascular production, generating approximately $46.8 billion in FY2025 revenue across 12 owned manufacturing facilities. The company's manufacturing operations are organized around its three therapeutic franchises: oncology—producing the PD-1 inhibitor Opdivo (nivolumab) through large-scale CHO cell culture and multi-column chromatography purification, CAR-T cell therapies Breyanzi and Abecma through patient-specific autologous cell processing, and targeted small molecules; hematology—manufacturing Revlimid through complex small molecule synthesis despite significant generic erosion; and cardiovascular—producing the Eliquis (apixaban) anticoagulant franchise that generates approximately $12 billion in annual sales. BMS's manufacturing strategy has evolved toward the "Growth Portfolio" concept—concentrating production resources on newer products (Opdivo-based combinations, Breyanzi, Camzyos, Reblozyl, Sotyktu) that are growing at 17% year-over-year while managing the decline of legacy products (Revlimid, Abraxane). The company operates 8 R&D centers with over 5,000 research personnel, investing approximately $6.8 billion annually (15.1% of revenue) in innovation that will ultimately demand new manufacturing platforms.

Strengths: Immuno-oncology manufacturing experience: BMS has manufactured Opdivo at commercial scale for over a decade, accumulating deep process knowledge in CHO cell culture, Protein A chromatography, and viral clearance specific to checkpoint inhibitor production. CAR-T manufacturing capability: The Breyanzi and Abecma cell therapy manufacturing platforms—encompassing viral vector production, autologous cell processing, and cryopreserved patient-specific supply chains—represent specialized competencies with significant barriers to entry. Cardiovascular manufacturing stability: The Eliquis franchise provides high-volume, high-reliability manufacturing revenue that funds investment in the Growth Portfolio and pipeline development.

Weaknesses: Legacy portfolio manufacturing drag: Revlimid, facing established generic competition with annualized revenue declines of 49%, occupies manufacturing capacity and quality system resources that must be systematically transferred to Growth Portfolio products. CAR-T capacity constraints: Autologous cell therapy manufacturing—with per-patient processing times of 2-3 weeks, vein-to-vein logistics complexity, and limited manufacturing slots—constrains Breyanzi and Abecma revenue growth independent of commercial demand. Eliquis patent cliff approaching: The loss of Eliquis exclusivity beginning in 2026-2028 will create a manufacturing volume gap that the Growth Portfolio's current trajectory does not yet fully bridge, requiring accelerated pipeline-to-manufacturing translation.

Legend Biotech has emerged as one of the most successful cell therapy companies globally, with its BCMA-targeted CAR-T therapy CARVYKTI achieving approximately $1.9 billion in global end-user sales during 2025. The company recorded $627 million in recognized revenue and has treated over 10,000 patients across 18 markets worldwide. A collaboration with Johnson & Johnson has enabled rapid global commercial expansion and manufacturing capacity buildout.

Strengths: CARVYKTI's exceptional clinical data with high complete response rates; successful expansion into earlier multiple myeloma treatment lines; state-of-the-art manufacturing facility in Raritan, New Jersey (10,000-patient annual capacity); cash reserves of $835 million supporting R&D and expansion; 100% pure-play CGT focus ensuring undivided strategic attention.

Weaknesses: Single-product dependency on CARVYKTI with limited pipeline diversification; foreign exchange exposure evidenced by $57.3M unrealized FX losses; still-nascent commercial infrastructure in emerging markets compared to big pharma peers; reliance on Janssen partnership for certain manufacturing and distribution capabilities.

Sarepta Therapeutics is the global leader in gene therapy and RNA-targeted therapeutics for rare neuromuscular diseases, generating $1.86 billion in net product revenue during 2025. Its Duchenne muscular dystrophy (DMD) gene therapy ELEVIDYS achieved $899 million in sales, while its PMO-based RNA therapies contributed $966 million. The company's strategic restructuring, including a 36% workforce reduction, has positioned it for sustained cash flow generation.

Strengths: Unique dual-platform approach covering both gene therapy (AAV) and RNA-targeted (PMO) modalities; ELEVIDYS label expansion to broader DMD patient population driving revenue acceleration; global partnership with Roche for ex-US commercialization; deep rare disease expertise with strong patient community relationships; cash reserves exceeding $950 million post-restructuring.

Weaknesses: Significant safety concerns with ELEVIDYS-associated acute liver failure cases leading to FDA black box warning; 36% workforce reduction may impact long-term innovation capacity; high dependency on DMD market with limited pipeline diversification; manufacturing relies on external CDMO partnerships rather than internal capacity.

Vertex Pharmaceuticals has established itself as a pioneer in CRISPR-based gene editing through its groundbreaking therapy CASGEVY, the first ever approved CRISPR/Cas9 gene-edited cell therapy. During 2025, Vertex generated approximately $120 billion total revenue while CASGEVY contributed $116 million. The product achieved 90% insurance coverage in the US and expanded to 12 countries, treating patients with sickle cell disease and transfusion-dependent beta-thalassemia.

Strengths: Pioneering first-in-class CRISPR gene-edited therapy with strong market adoption; exceptional market access achievement with 90% US insurance coverage; robust $120 billion revenue base providing R&D funding stability; expanding authorized treatment center network globally; active pipeline in type 1 diabetes stem cell therapy and pain management.

Weaknesses: CASGEVY remains a small revenue contributor relative to Vertex's CF franchise; manufacturing bottleneck due to limited authorized treatment center capacity; CASGEVY's high price point ($2.2M per patient) limits patient volume; type 1 diabetes program experienced manufacturing-related clinical hold in 2025.

Lonza Group is the world's largest contract development and manufacturing organization (CDMO), serving as the foundational manufacturing partner for the global CGT industry. In 2025, Lonza generated 6.53 billion Swiss francs ($7.4 billion) in revenue with a 31.6% EBITDA margin. The company scored a landmark achievement by winning the commercial manufacturing contract for CASGEVY at its Geleen, Netherlands facility, the first factory approved across FDA, EMA, and MHRA for CRISPR therapy production.

Strengths: Unmatched global manufacturing infrastructure with 30+ facilities across 5 continents; exclusive CASGEVY commercial manufacturing contract demonstrating CGT capability; 31.6% EBITDA margin showcasing pricing power and operational efficiency; end-to-end capabilities from cell culture media to viral vector production; strong balance sheet supporting continuous capacity expansion.

Weaknesses: CGT-specific Specialized Modalities division experienced 3% revenue decline in 2025 due to early-stage biotech funding headwinds; foreign exchange impact from USD/CHF volatility affecting reported results; capital-intensive business model requiring continuous major investment; strategic complexity from managing multiple technology platforms.

Thermo Fisher Scientific Inc. is the world's leading provider of scientific services, headquartered in Waltham, Massachusetts, USA. Through its four business segments—Life Sciences, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services—it delivers comprehensive workflow solutions from basic research to clinical application for global pharmaceutical and biotech companies, research institutions, and clinical labs. With revenue of approximately US$50 billion in FY2025, Thermo Fisher has become an infrastructural partner underpinning innovation in the global life sciences and healthcare sectors. This is achieved by leveraging the strong customer stickiness derived from its end-to-end "sample to insight" product and service portfolio, its long-established technological leadership in high-end analytical instruments and life science tools, and its deep understanding of research funding trends and global health priorities.

Strengths: Thermo Fisher's core strengths are the high customer switching costs and synergistic value created by its "one-stop-shop" product and service ecosystem, formed through continuous strategic acquisitions, which nearly covers the entire biopharma R&D and manufacturing workflow; and its strong technological leadership and channel control in key niche markets such as mass spectrometry, electron microscopy, and bioprocessing consumables.

Weaknesses: The company's main weaknesses are the high correlation of its performance with R&D expenditure budgets and capital investment cycles of governments and private sectors globally (particularly in the US and Europe), making it susceptible to macroeconomic and policy volatility; the ongoing challenges its operations face from stringent worldwide regulatory environments for medical devices and diagnostic products; and the persistent competitive pressure from specialized players in certain market segments.

Minaris Advanced Therapies emerged in 2025 as a transformative new entity in the CGT CDMO landscape, formed through the strategic merger of Altaris-owned Minaris Regenerative Medicine and the acquired WuXi Advanced Therapies (formerly WuXi ATU) manufacturing assets. This combination creates a uniquely positioned, geopolitically de-risked CGT manufacturing powerhouse with facilities across the US, UK, and Japan. The merger was driven by the BIOSECURE Act and growing demand for supply chain diversification away from China-headquartered providers.

Strengths: Best-in-class lentiviral vector and AAV manufacturing capabilities inherited from WuXi ATU; geopolitically neutral ownership structure eliminating BIOSECURE Act concerns; established FDA and EMA regulatory track record across multiple approved therapies; multi-continent manufacturing footprint providing supply chain redundancy; strong pipeline of customer programs transitioning from development to commercialization.

Weaknesses: Private ownership limits financial transparency and public market validation; ongoing integration complexity combining two distinct organizational cultures; customer transition period with potential order disruptions; relatively small scale compared to Lonza and Thermo Fisher; limited direct experience as an independent entity.

GenScript Biotech has established itself as a dominant force in the gene synthesis and CGT CDMO market, achieving $959.5 million in 2025 revenue with extraordinary 61.4% year-over-year growth. Its ProBio CDMO subsidiary experienced explosive 309.1% revenue growth to $388.7 million, driven by surging demand for plasmid DNA, viral vector manufacturing, and gene synthesis services. GenScript's unique ecosystem approach, encompassing parent company gene synthesis, ProBio CDMO, and Legend Biotech (cell therapy), creates an integrated CGT value chain.

Strengths: Dominant position in global gene synthesis market with 66,000+ active customers; ProBio CDMO's 309% growth demonstrating exceptional market demand; unique ecosystem spanning from research reagents to commercial cell therapy; Lights-out factory strategy with AI-driven automation; global expansion including new US and European GMP facilities.

Weaknesses: Parent company carrying net losses from legacy R&D investments; geographic exposure to US-China trade tensions and BIOSECURE Act uncertainty; potential conflicts of interest as both CDMO and cell therapy (Legend) parent; integration complexity from rapid expansion across multiple business lines.